In this issue:
Early decrease in ctDNA prognostic for favourable outcomes
Neighbourhood social vulnerability linked to poor outcomes
ARIEL4: rucaparib vs chemo for BRAC1/2 mutated ovarian cancer
Exercise may alleviate CIPN in patients with ovarian cancer
Cediranib ± olaparib not superior to chemo in platinum-refractory disease
Heterogeneity in the duration of PARP inhibitor maintenance
PEACOCC: pembrolizumab beneficial in previously treated advanced OCCC
Survival not impacted by intracycle treatment delays
Adverse events common in the placebo arm of the SOLO2 trial
Please login below to download this issue (PDF)